Trial Spotlight

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

ACCRU Trial Spotlight High-risk myeloma remains a perplexing [...]

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma2022-12-15T21:48:27+00:00
Copyright © | ACCRU.org | Terms & Privacy
Copyright ©
ACCRU.org
Terms & Privacy
The information and content provided on this website is made available for informational purposes. While the Academic and Community Cancer Research United (ACCRU) network strives to provide accurate and up-to-date information, this information may change quickly and become out-of-date or incomplete. In addition, some information may be provided through links to other websites that are not affiliated with ACCRU. ACCRU cannot guarantee information that may be found through these links. The information and content presented herein is not intended to replace the advice of a health care provider.
Copyright © Academic and Community Cancer Research United. Medical images courtesy of Mayo Foundation for Medical Education and Research. All rights reserved.
FacebookXInstagramPinterest
Go to Top